Serum and urine biomarkers for detecting clinically significant prostate cancer

被引：35

作者：

Becerra, Maria F. ^{[1
]}

Atluri, Venkatasai S. ^{[1
]}

Bhattu, Amit S. ^{[1
]}

Punnen, Sanoj ^{[1
,2
]}

机构：

[1] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33146 USA

[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33146 USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2021年 / 39卷 / 10期

关键词：

Prostate cancer; Clinically significant cancer; Urine biomarkers; Serum biomarkers; ANTIGEN; UTILITY; PANEL; PCA3;

D O I：

10.1016/j.urolonc.2020.02.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Since the "prostate-specific antigen (PSA) era," we have seen an increase in unnecessary biopsies, which has ultimately lead to an overtreatment of low-risk cancers. Given the limitations of prostate-specific antigen and the invasive nature of prostate biopsy several serum and urinary biomarkers have been developed. In this paper, we provide a comprehensive review of the available biomarkers for the detection clinically significant prostate cancer namely PHI, 4Kscore, PCA3, MiPS, SelectMDx, ExosomeDX. Current literature suggests that these biomarkers can improve detection of clinically significant prostate cancer reducing overtreatment and making treatment strategies more cost-effective. Nevertheless, large prospective studies with head-to-head-comparisons of the available biomarkers are necessary to fully assess the potential of incorporating biomarkers in routine clinical practice. (c) 2020 Elsevier Inc. All rights reserved.

引用

页码：686 / 690

页数：5

共 31 条

[1] A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range [J].

Catalona, William J. ;

Partin, Alan W. ;

Sanda, Martin G. ;

Wei, John T. ;

Klee, George G. ;

Bangma, Chris H. ;

Slawin, Kevin M. ;

Marks, Leonard S. ;

Loeb, Stacy ;

Broyles, Dennis L. ;

Shin, Sanghyuk S. ;

Cruz, Amabelle B. ;

Chan, Daniel W. ;

Sokoll, Lori J. ;

Roberts, William L. ;

van Schaik, Ron H. N. ;

Mizrahi, Isaac A. .

JOURNAL OF UROLOGY, 2011, 185 (05) :1650-1655

[2] A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings [J].

Chiu, Peter K-F ;

Ng, Chi-Fai ;

Semjonow, Axel ;

Zhu, Yao ;

Vincendeau, Sibastien ;

Houlgatte, Alain ;

Lazzeri, Massimo ;

Guazzoni, Giorgio ;

Stephan, Carsten ;

Haese, Alexander ;

Bruijne, Ilse ;

Teoh, Jeremy Yuen-Chun ;

Leung, Chi Ho ;

Casale, Paola ;

Chiang, Chih Hung ;

Tan, Lincoln Guan-Lim ;

Chiong, Edmund ;

Huang, Chao Yuan ;

Wu, Hsi Chin ;

Nieboer, Daan ;

Ye, Ding-Wei ;

Bangma, Chris H. ;

Roobol, Monique J. .

EUROPEAN UROLOGY, 2019, 75 (04) :558-561

[3] Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis [J].

Cui, Yong ;

Cao, Wenzhou ;

Li, Quan ;

Shen, Hua ;

Liu, Chao ;

Deng, Junpeng ;

Xu, Jiangfeng ;

Shao, Qiang .

SCIENTIFIC REPORTS, 2016, 6

[4] Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer [J].

Druskin, Sasha C. ;

Tosoian, Jeffrey J. ;

Young, Allen ;

Collica, Sarah ;

Srivastava, Arnav ;

Ghabili, Kamyar ;

Macura, Katarzyna J. ;

Carter, H. Ballentine ;

Partin, Alan W. ;

Sokoll, Lori J. ;

Ross, Ashley E. ;

Pavlovich, Christian P. .

BJU INTERNATIONAL, 2018, 121 (04) :619-626

[5] The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population [J].

Gnanapragasam, V. J. ;

Burling, K. ;

George, A. ;

Stearn, S. ;

Warren, A. ;

Barrett, T. ;

Koo, B. ;

Gallagher, F. A. ;

Doble, A. ;

Kastner, C. ;

Parker, R. A. .

SCIENTIFIC REPORTS, 2016, 6

[6] Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study [J].

Govers, Tim M. ;

Hessels, Daphne ;

Vlaeminck-Guillem, Virginie ;

Schmitz-Draeger, Bernd J. ;

Stief, Christian G. ;

Martinez-Ballesteros, Claudio ;

Ferro, Matteo ;

Borque-Fernando, Angel ;

Rubio-Briones, Jose ;

Sedelaarll, J. P. Michiel ;

van Criekinge, Wim ;

Schalken, Jack A. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2019, 22 (01) :101-109

[7] Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial [J].

Johansson, Eva ;

Steineck, Gunnar ;

Holmberg, Lars ;

Johansson, Jan-Erik ;

Nyberg, Tommy ;

Ruutu, Mirja ;

Bill-Axelson, Anna .

LANCET ONCOLOGY, 2011, 12 (09) :891-899

[8] Biomarkers in prostate cancer - Current clinical utility and future perspectives [J].

Kretschmer, Alexander ;

Tilki, Derya .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 120 :180-193

[9] Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer [J].

Leyten, Gisele H. J. M. ;

Hessels, Daphne ;

Smit, Frank P. ;

Jannink, Sander A. ;

de Jong, Hans ;

Melchers, Willem J. G. ;

Cornel, Erik B. ;

de Reijke, Theo M. ;

Vergunst, Henk ;

Kil, Paul ;

Knipscheer, Ben C. ;

Hulsbergen-van de Kaa, Christina A. ;

Mulders, Peter F. A. ;

van Oort, Inge M. ;

Schalken, Jack A. .

CLINICAL CANCER RESEARCH, 2015, 21 (13) :3061-3070

[10] Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer [J].

Leyten, Gisele H. J. M. ;

Hessels, Daphne ;

Jannink, Sander A. ;

Smit, Frank P. ;

de Jong, Hans ;

Cornel, Erik B. ;

de Reijke, Theo M. ;

Vergunst, Henk ;

Kil, Paul ;

Knipscheer, Ben C. ;

van Oort, Inge M. ;

Mulders, Peter F. A. ;

Hulsbergen-van de Kaa, Christina A. ;

Schalken, Jack A. .

EUROPEAN UROLOGY, 2014, 65 (03) :534-542

← 1 2 3 4 →